Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study

Area of Science:

• Pediatric Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Major Depressive Disorder (MDD) is a significant concern in pediatric populations.
• Limited treatment options exist for children with MDD, necessitating research into novel pharmacotherapies.
• Vortioxetine has shown efficacy in adult MDD, but its use in younger children requires investigation.

Purpose of the Study:

• To assess the efficacy, safety, and tolerability of vortioxetine in children aged 7 to 11 years diagnosed with MDD.
• To compare vortioxetine's effectiveness against placebo and fluoxetine in this pediatric population.
• To evaluate treatment-emergent adverse events associated with vortioxetine use in children.

Main Methods:

• A randomized, double-blind, placebo-controlled trial was conducted following a single-blind lead-in period.
• Patients with incomplete symptom improvement received brief psychosocial intervention plus placebo, vortioxetine (10 mg/day or 20 mg/day), or fluoxetine (20 mg/day).
• The primary endpoint was the change in Children's Depression Rating Scale-Revised (CDRS-R) total score from baseline to week 8.

Main Results:

• No statistically significant difference in CDRS-R score improvement was observed between vortioxetine (average of 10mg and 20mg doses) and placebo (p=0.0937).
• Enrollment to the fluoxetine arm was stopped early based on an interim analysis.
• Treatment-emergent adverse events were reported by 47% of patients, with nausea being most common in vortioxetine groups (11.1%-12.6%).

Conclusions:

• Vortioxetine did not demonstrate statistically significant efficacy in treating major depressive disorder in children aged 7-11 years.
• The safety and tolerability profile of vortioxetine in this pediatric cohort was consistent with findings in adolescents and adults.
• No significant safety concerns beyond those expected were identified during the study.